Adaptimmune Therapeutics plc Company Name:
ADAP Stock Symbol:
NASDAQ Market:
News, Short Squeeze, Breakout and More Instantly...
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and ...
Introduction Cancer is the second leading cause of death globally, with an estimated 17.0 million new cases and 9.5 million deaths in 2018. By 2040, the global burden is expected to grow to 27.5 million new cases and 16.3 million deaths. Although most money in clinical development has ...
- Clinical responses in seven out of 14 patients with synovial sarcoma by RECIST 1.1 - - Clinical benefit in 13 out of 14 patients - - One RECIST response maintained for more than 9 months after SPEAR T-cell infusion - PHILADELPHIA and OXFORDSHIRE, United Kingdom, Nov. 16, 2019 ...